Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Structural Basis of Colchicine-Site targeting Acylhydrazones active against Multidrug-Resistant Acute Lymphoblastic Leukemia

Full text
Show less -
Cury, Nathalia Moreno [1, 2] ; Muehlethaler, Tobias [3] ; Albertoni Laranjeira, Angelo Brunelli [2] ; Canevarolo, Rafael Renatino [2] ; Zenatti, Priscila Pini [2] ; Lucena-Agell, Daniel [4] ; Barasoain, Isabel [4] ; Song, Chunhua [5] ; Sun, Dongxiao [5] ; Dovat, Sinisa [5] ; Yunes, Rosendo Augusto [6] ; Prota, Andrea Enrico [3] ; Steinmetz, Michel Olivier [3, 7] ; Fernando Diaz, Jose [4] ; Yunes, Jose Andres [8, 2]
Total Authors: 15
[1] Univ Estadual Campinas, Grad Program Genet & Mol Biol, BR-13083210 Campinas, SP - Brazil
[2] Ctr Infantil Boldrini, Lab Biol Mol, Rua Dr Gabriel Porto 1270, BR-13083210 Campinas, SP - Brazil
[3] Paul Scherrer Inst, Div Biol & Chem, Lab Biomol Res, CH-5232 Villigen - Switzerland
[4] CSIC, Ctr Invest Biol, E-28006 Madrid - Spain
[5] Penn State Univ, Dept Pediat, Coll Med, Hershey, PA 17033 - USA
[6] Univ Fed Santa Catarina, Dept Chem, BR-88040900 Florianopolis, SC - Brazil
[7] Univ Basel, Biozentrum, CH-4056 Basel - Switzerland
[8] Univ Estadual Campinas, Fac Med Sci, Genet Dept, BR-13083887 Campinas, SP - Brazil
Total Affiliations: 8
Document type: Journal article
Source: ISCIENCE; v. 21, p. 95+, NOV 22 2019.
Web of Science Citations: 0

Tubulin is one of the best validated anti-cancer targets, but most anti-tubulin agents have unfavorable therapeutic indexes. Here, we characterized the tubulin-binding activity, the mechanism of action, and the in vivo anti-leukemia efficacy of three 3,4,5-trimethoxy-N-acylhydrazones. We show that all compounds target the colchicine-binding site of tubulin and that none is a substrate of ABC transporters. The crystal structure of the tubulin-bound N-(1'-naphthyl)-3,4,5-trimethoxybenzohydrazide (12) revealed steric hindrance on the T7 loop movement of beta-tubulin, thereby rendering tubulin assembly incompetent. Using dose escalation and short-term repeated dose studies, we further report that this compound class is well tolerated to >100 mg/kg in mice. We finally observed that intraperitoneally administered compound 12 significantly prolonged the overall survival of mice transplanted with both sensitive and multidrug-resistant acute lymphoblastic leukemia (ALL) cells. Taken together, this work describes promising colchicine-site-targeting tubulin inhibitors featuring favorable therapeutic effects against ALL and multidrug-resistant cells. (AU)

FAPESP's process: 14/08247-8 - Preclinical studies of novel inhibitors of DNA methyltransferase in acute leukemia
Grantee:Nathalia Moreno Cury
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 17/14737-6 - Preclinical study of a colchicine binding site tubulin inhibitor with potent anti-leukemia activity and low toxicity
Grantee:Nathalia Moreno Cury
Support type: Scholarships abroad - Research Internship - Doctorate